Tuning the performance of CAR T cell immunotherapies.

BMC Biotechnol · 2019 · PMC6884819 · PMID 31783836

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Modifications of CAR structure also involved minor, yet highly significant variations, such as the point-mutations of tyrosine residues in the CD3zeta tail of an anti-CD19 CAR [ 44 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.